Masu Hana Ciwon Menin: Maganin da ke da Alaƙa da Ciwon Leukemia Mai Tsanani

Cutar sankarar myeloid mai tsanani (AML) cuta ce mai sarkakiya kuma mai bambancin jini wadda ke nuna yaduwar ƙwayoyin halittar myeloid progenitor a clonal. Duk da ci gaba a magani, warkar da AML ya kasance mai wahala, musamman ga marasa lafiya da ke da takamaiman matsalolin kwayoyin halitta. Binciken da aka yi kwanan nan an nuna a cikin mujallar. Jini suna jaddada muhimmancin magungunan hana Menin, suna nuna yuwuwarsu ta kawo sauyi ga maganin AML.

Matsayin Epigenetics a cikin AML

Gyaran ƙwayoyin halittar jini, kamar su methylation na DNA da gyaran histone, canje-canje ne masu canzawa waɗanda ke daidaita bayyanar kwayoyin halitta ba tare da canza jerin DNA ba. Waɗannan canje-canjen suna taka muhimmiyar rawa a cikin ci gaban AML. Yin niyya ga waɗannan hanyoyin epigenetic masu canzawa yana ba da sabuwar hanyar magani.

Histones, muhimman sunadaran da ke cikin marufi na DNA, suna fuskantar gyare-gyare bayan fassara kamar acetylation da methylation, waɗanda ke tasiri ga kwafi na kwayar halitta. Menin, wani furotin mai siffar siffa da kwayar halittar MEN1 ta ƙunsa, yana da mahimmanci ga tsarin epigenetic. Yana hulɗa da histone methyltransferase KMT2A da sauran abokan hulɗa don daidaita bayyanar kwayar halitta. A cikin AML, Menin yana sauƙaƙe shirye-shiryen kwafi na oncogenic, musamman ta hanyar haɓaka kwayoyin halittar HOXA da MEIS1, waɗanda sune manyan abubuwan da ke haifar da AML mai siffar KMT2A da NPM1 mai canzawa.

Masu Hana Menin: Nasara a Maganin AML

Masu hana Menin ƙananan ƙwayoyin halitta ne da aka tsara don wargaza hulɗar da ke tsakanin Menin da KMT2A, ta haka ne ke toshe hanyoyin fassara kwayoyin halitta. Waɗannan masu hana sun nuna tasiri mai ban mamaki a cikin nazarin asibiti da na asibiti, musamman ga AML da aka sake tsarawa da kuma wanda aka canza daga KMT2A zuwa NPM1, waɗanda suka haɗa da wani ɓangare mai mahimmanci na shari'o'in AML.

An amince da amfani da maganin hana Menin na farko, revumenib (SNDX-5613), a asibiti, tare da wasu da dama, ciki har da ziftomenib (KO-539) da bleximenib, waɗanda aka yi musu gwaje-gwaje na asibiti. Gwajin AUGMENT-101 ya nuna cewa revumenib ya sami jimlar ƙimar amsawa (ORR) na 53% a cikin AML da aka sake dawowa ko aka sake yin amfani da shi (R/R), tare da illolin da za a iya sarrafawa kamar su tsawaitawa da rarrabuwar QTc. Hakazalika, sakamakon farko daga gwaje-gwajen KOMET-001 da KOMET-008 da suka kimanta ziftomenib sun nuna alamun sassauci da bayanan aminci.

Ana kuma binciken hanyoyin haɗin gwiwa don haɓaka ingancin magungunan hana Menin. Nazarin da aka haɗa da revumenib tare da magungunan hypomethylating kamar azacitidine da venetoclax sun ba da rahoton cewa adadin amsawar ya kusan kashi 100% a cikin marasa lafiya da marasa lafiya na AML masu lafiya da marasa lafiya, kodayake ana buƙatar ƙarin bincike tare da manyan ƙungiyoyi.

Umarnin Tsaro da na Nan gaba

Magungunan hana ciwon Menin gabaɗaya suna nuna kyakkyawan yanayin aminci, inda yawancin illolin da ke tattare da su ana iya sarrafa su kuma ana iya jurewa. Abubuwan da ke faruwa a yau da kullun sun haɗa da alamun cututtukan ciki, cytopenias, da kuma ciwon bambance-bambance. Sifofin maganin da Hukumar Abinci da Magunguna ta Amurka (FDA) ta ba wa revumenib da ziftomenib sun nuna mahimmancin masu hana ciwon Menin wajen magance buƙatun da ba a cika ba a maganin AML.

Bayanan asibiti masu kyau game da masu hana cutar Menin suna nuna wani mataki mai kyau a cikin maganin AML, wanda ke ba da bege ga marasa lafiya da ke da ƙalubalen tarihi a fannin kwayoyin halitta. Yayin da bincike ke ci gaba, waɗannan hanyoyin magani suna shirye don sake fasalta ma'aunin kulawa ga AML.

Cibiyar Kiwon Lafiya ta Duniya ta BIOOCUS ta ci gaba da jajircewa wajen amfani da sabbin dabarun zamani kamar hana Menin don samar da magunguna masu inganci ga marasa lafiya a duk duniya.